From fecal, food, or environmental matrices, we selectively isolate E. faecium, purify colonies, and preserve early banks. Screening ranks candidates by growth kinetics, acid/bile/heat tolerance, adhesion proxies, and preliminary safety markers. We flag atypical phenotypes while keeping detailed culture histories and QC metadata. Deliverables prioritize E. faecium strains that align with your research aims and downstream fermentation or formulation reproducibly.
Species-level identification for E. faecium combines MALDI-TOF or 16S rRNA with targeted PCR; optional whole-genome sequencing resolves clades, AMR determinants, and virulence markers. We provide annotated assemblies, MLST, plasmid profiling, and phylogeny snapshots linked to lab records. Results validate E. faecium provenance, de-risk sample exchange, and support repository submission, IP strategy, and future comparative genomics across strain libraries with traceability.
We perform standardized MIC panels and gradient strips to quantify E. faecium susceptibility across sentinel antibiotics, including vancomycin and linezolid. Results reconcile genotype and phenotype when paired with WGS, clarifying AMR burdens and informing biosafety categorization. AST data for E. faecium guide co-culture designs, media choices, decontamination policies, and appropriate containment for subsequent functional assays and bioprocessing steps and stewardship.
Our mechanism-focused screens map E. faecium activities: bacteriocin-like inhibition spectra, competitive exclusion against indicators, carbohydrate utilization, biofilm behavior, and stress responses. We fractionate active supernatants, quantify units, and apply LC-MS/MS to nominate peptides. Integrating genomics and phenotypes, we attribute E. faecium functions to candidate effectors, generating decision-ready dossiers for prioritizing strains and designing rational follow-up experiments with thresholds and reproducibility.
Using epithelial monolayers, mucus-rich co-cultures, and organoid-derived barriers, we evaluate how E. faecium influences TEER, tight-junction proteins, and epithelial transcriptional programs. Co-exposure with pathobionts models colonization resistance. We normalize MOI, viability, and exposure time, reporting cytokine cross-talk and barrier metrics. These assays contextualize E. faecium strain effects in host-relevant settings without implying clinical outcomes or claims. Include controls and replicates.
We profile immune signaling induced by E. faecium using human PBMCs, monocyte-derived macrophages, or splenocytes. Cytokines and chemokines (e.g., IL-10, IL-6, TNF-α, IFN-γ) are quantified across live cells, heat-killed preparations, and cell-free supernatants. Flow cytometry and transcriptomics refine mode-of-action hypotheses, distinguishing E. faecium strains by innate polarization patterns and adaptive-leaning signatures relevant to research-grade dossiers. Batch metadata ensures assay comparability.
We translate E. faecium from flasks to controlled bioreactors, optimizing media, pH, DO, and feeding to preserve target phenotypes. Stress-conditioning and bile or acid challenges are applied when appropriate. We deliver biomass or cell banks with viability curves, metabolite profiles, and stability snapshots. Process parameters and in-process controls enable reproducibility and scale-up while safeguarding E. faecium's functional attributes for reproducibility.
We stabilize E. faecium via lyophilization or spray-drying with protectants, moisture control, and optional microencapsulation. Formats are benchmarked by viable counts, residual moisture, reconstitution, and accelerated stability under temperature and humidity regimes. We document carrier compatibility and dosing calculations for research workflows. Each E. faecium lot ships with batch records, release QC, and storage guidance supporting consistent experimental performance reliably.
